JP2019517477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517477A5 JP2019517477A5 JP2018562097A JP2018562097A JP2019517477A5 JP 2019517477 A5 JP2019517477 A5 JP 2019517477A5 JP 2018562097 A JP2018562097 A JP 2018562097A JP 2018562097 A JP2018562097 A JP 2018562097A JP 2019517477 A5 JP2019517477 A5 JP 2019517477A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- double
- composition
- stranded oligonucleotide
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 14
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 14
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 229940126586 small molecule drug Drugs 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- 230000008685 targeting Effects 0.000 claims 8
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 230000000149 penetrating effect Effects 0.000 claims 6
- 229940123237 Taxane Drugs 0.000 claims 5
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 5
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 102400000058 Neuregulin-1 Human genes 0.000 claims 2
- 108090000556 Neuregulin-1 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 108010039918 Polylysine Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 230000002518 glial effect Effects 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229920000656 polylysine Polymers 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342829P | 2016-05-27 | 2016-05-27 | |
| US62/342,829 | 2016-05-27 | ||
| PCT/US2017/034719 WO2017205764A1 (en) | 2016-05-27 | 2017-05-26 | Drug-delivery nanoparticles and treatments for drug-resistant cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517477A JP2019517477A (ja) | 2019-06-24 |
| JP2019517477A5 true JP2019517477A5 (enExample) | 2020-07-02 |
Family
ID=60411649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562097A Pending JP2019517477A (ja) | 2016-05-27 | 2017-05-26 | 薬物抵抗性癌のための薬物送達ナノ粒子および治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190175747A1 (enExample) |
| EP (1) | EP3463468A4 (enExample) |
| JP (1) | JP2019517477A (enExample) |
| KR (1) | KR20190013929A (enExample) |
| CN (1) | CN109475636A (enExample) |
| AU (1) | AU2017271662A1 (enExample) |
| BR (1) | BR112018074304A2 (enExample) |
| CA (1) | CA3025348A1 (enExample) |
| EA (1) | EA201892797A1 (enExample) |
| IL (1) | IL263227A (enExample) |
| MX (1) | MX2018014576A (enExample) |
| SG (1) | SG11201810403VA (enExample) |
| WO (1) | WO2017205764A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CA2881582A1 (en) * | 2012-08-03 | 2014-02-06 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| PL2993983T3 (pl) | 2013-05-08 | 2020-09-07 | Cedars-Sinai Medical Center | Ukierunkowane korole o toksyczności wobec guza i do mri |
| EP3791889B1 (en) | 2014-01-17 | 2024-02-21 | Cedars-Sinai Medical Center | C-met receptor targeting constructs and uses thereof |
| WO2018067526A1 (en) * | 2016-10-03 | 2018-04-12 | Eos Biosciences, Inc. | Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles |
| EP3735245A4 (en) * | 2018-01-02 | 2021-10-27 | Cedars-Sinai Medical Center | NANOPARTICLES ALLOWING TARGETED ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| CA3149992A1 (en) * | 2019-09-06 | 2021-03-11 | The Regents Of The University Of California | Nucleic acid-mediated delivery of therapeutics |
| CN115282283B (zh) * | 2022-06-21 | 2024-11-29 | 上海交通大学 | 一种小分子药物-寡核苷酸偶联物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391723A (en) * | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| WO2009009441A2 (en) * | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) * | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| EP2473160A4 (en) * | 2009-09-01 | 2015-06-03 | Univ Northwestern | ADMINISTRATION OF THERAPEUTIC AGENTS WITH OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS SUPPORT |
| EP3129066B1 (en) * | 2014-04-04 | 2020-08-12 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle |
| SG10201806064XA (en) * | 2014-08-27 | 2018-08-30 | Peptimed Inc | Anti-tumor compositions and methods |
-
2017
- 2017-05-26 US US16/304,501 patent/US20190175747A1/en not_active Abandoned
- 2017-05-26 KR KR1020187037729A patent/KR20190013929A/ko not_active Ceased
- 2017-05-26 EA EA201892797A patent/EA201892797A1/ru unknown
- 2017-05-26 EP EP17803677.8A patent/EP3463468A4/en not_active Withdrawn
- 2017-05-26 SG SG11201810403VA patent/SG11201810403VA/en unknown
- 2017-05-26 CN CN201780043181.8A patent/CN109475636A/zh active Pending
- 2017-05-26 MX MX2018014576A patent/MX2018014576A/es unknown
- 2017-05-26 BR BR112018074304A patent/BR112018074304A2/pt not_active Application Discontinuation
- 2017-05-26 CA CA3025348A patent/CA3025348A1/en not_active Abandoned
- 2017-05-26 WO PCT/US2017/034719 patent/WO2017205764A1/en not_active Ceased
- 2017-05-26 AU AU2017271662A patent/AU2017271662A1/en not_active Abandoned
- 2017-05-26 JP JP2018562097A patent/JP2019517477A/ja active Pending
-
2018
- 2018-11-22 IL IL263227A patent/IL263227A/en unknown
-
2025
- 2025-01-10 US US19/017,303 patent/US20250255978A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Nanoparticles for combination drug therapy | |
| Sutton et al. | Neoadjuvant therapy for pancreas cancer: past lessons and future therapies | |
| Abu Samaan et al. | Paclitaxel’s mechanistic and clinical effects on breast cancer | |
| Socinski et al. | A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer | |
| Mohammadpour et al. | Applications of two-dimensional nanomaterials in breast cancer theranostics | |
| Wu et al. | Nanomedicine applications in the treatment of breast cancer: current state of the art | |
| Farley et al. | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study | |
| Liu et al. | Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro | |
| Seligmann et al. | Tubulin: an example of targeted chemotherapy | |
| Mu et al. | Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook | |
| Pandey et al. | Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy | |
| JP2013533232A5 (enExample) | ||
| JP2016041071A5 (enExample) | ||
| Jones et al. | Tackling breast cancer chemoresistance with nano-formulated siRNA | |
| JP2017514800A5 (enExample) | ||
| Cowherd et al. | A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer | |
| JP2014526456A5 (enExample) | ||
| Miller et al. | Nanomedicine in chemoradiation | |
| Liu et al. | Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab–DNA conjugates | |
| Yusoh et al. | Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies | |
| RU2016124731A (ru) | Рецептор-направленные конструкции и их применение | |
| JP2019531268A5 (enExample) | ||
| Roy et al. | A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm | |
| JP2019529571A5 (enExample) | ||
| Jia et al. | Self‐Assembled DNA Nanostructures for Drug Delivery |